Literature DB >> 11166086

Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.

J K Yao1, R Reddy, D P van Kammen.   

Abstract

Albumin and bilirubin are metal-binding proteins, shown to possess free radical scavenging properties, and may thus be selective antioxidants. In the present study we examined whether individual plasma antioxidants such as albumin and bilirubin, which significantly contribute to total antioxidant status (TAS), are reduced in patients with schizophrenia. We prospectively studied plasma antioxidant proteins, i.e. albumin and bilirubin, in male veteran schizophrenic patients using a within-subject, repeated measures, on-off-on haloperidol treatment design, as well as age- and sex-matched healthy volunteers. Male patients with schizophrenia either during haloperidol treatment (n=46) or in a drug-free condition (n=35) had significantly lower levels of both plasma albumin and bilirubin compared with age- and sex-matched healthy volunteers (n=31). Such reductions of plasma antioxidant proteins in schizophrenic patients appear to be age-related changes, in contrast to those observed in healthy volunteers. On the other hand, levels of plasma albumin and bilirubin were not significantly affected by haloperidol treatment, haloperidol withdrawal, or length of drug-free period. Moreover, plasma TAS was not influenced significantly by cigarette smoking, even though it may selectively decrease plasma bilirubin but not albumin levels. The present findings, taken together with our previous results of reduced plasma TAS and uric acid, as well as an increased Red blood cell superoxide dismutase, lend further support to the hypothesis that a defect in the antioxidant defense system exists in schizophrenia that may lead to oxidative damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11166086     DOI: 10.1016/s0165-1781(00)00230-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  22 in total

1.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study.

Authors:  Hui-chun Li; Qiao-zhen Chen; Ying Ma; Jun-fu Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

Review 2.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 3.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia?: Relationship Between Clinical Improvement and Episode Severity in Male Patients.

Authors:  Bülent Kadri Gültekin; Sermin Kesebir; Sevgi Gül Kabak; Ferzan Fikret Ergün; Elif Tatlidil Yaylaci
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

Review 5.  Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Authors:  Tanya T Nguyen; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

6.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

7.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Ling Yan Qi; Song Chen; Lian Yuan Cao; Da Chun Chen; Mei Hong Xiu; Fan Wang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

Review 8.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

9.  Elevated plasma F2-isoprostane levels in schizophrenia.

Authors:  Ellen E Lee; Lisa T Eyler; Owen M Wolkowitz; Averria Sirkin Martin; Chase Reuter; Helena Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-06-16       Impact factor: 4.939

10.  Assessment Causality in Associations Between Serum Uric Acid and Risk of Schizophrenia: A Two-Sample Bidirectional Mendelian Randomization Study.

Authors:  Qianqian Luo; Zheng Wen; Yuanfan Li; Zefeng Chen; Xinyang Long; Yulan Bai; Shengzhu Huang; Yunkun Yan; Rui Lin; Zengnan Mo
Journal:  Clin Epidemiol       Date:  2020-02-26       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.